岩藻多糖抗幽门螺杆菌作用的研究进展
Research Progress on the Anti-Helicobacter pylori Effect of Fucoidan
DOI: 10.12677/acm.2024.14123198, PDF,    科研立项经费支持
作者: 徐 颜, 郝静雯, 田字彬, 于亚男*:青岛大学附属医院消化内科,山东 青岛
关键词: 幽门螺杆菌岩藻多糖Helicobacter pylori Fucoidan
摘要: 幽门螺杆菌(Helicobacter pylori, Hp)被世界卫生组织(WHO)认定为I类致癌因子,全球Hp感染率高达40%。目前根除Hp的治疗方案是基于抑酸剂和抗生素的组合。但由于广泛和/或滥用抗生素,部分Hp菌株产生了抗生素耐药性,导致治疗失败。Hp通过其多种致病因子在胃粘膜中生存和定植,致病靶点多样化。近年来,开发可替代、有效且无害的根除或清除Hp物质成为研究热点。岩藻多糖因其具有抗黏附、抗氧化、抗毒性、免疫调节、抗凝血和抗感染等多种生物活性,显示出潜在的抗Hp作用。现有研究表明,岩藻多糖抗Hp的机制主要包括:阻止粘附定植于胃粘膜、直接或间接减轻胃粘膜炎症、减轻氧化应激及改善肠道微生态等。本综述将总结当前关于岩藻多糖抗Hp作用机制的研究进展,并探讨其在Hp根除治疗中的应用前景。
Abstract: Helicobacter pylori (Hp) has been classified as a Group I carcinogen by the World Health Organization (WHO), with a global infection rate reaching 40%. Currently, the standard treatment for eradicating Hp is based on a combination of acid suppressants and antibiotics. However, due to the widespread and/or improper use of antibiotics, some Hp strains have developed antibiotic resistance, often leading to treatment failure. Hp possesses a variety of pathogenic factors that allow it to survive and colonize the gastric mucosa, resulting in diverse pathogenic targets. In recent years, the development of alternative, effective, and harmless substances for the eradication or clearance of Hp has become a research hotspot. Fucoidan, with its multiple biological activities including anti-adhesion, antioxidant, antitoxic, immunomodulatory, anticoagulant, and anti-infection properties, has shown potential anti-Hp effects. Current research indicates that the mechanisms by which fucoidan exerts its anti-Hp effects include preventing adhesion and colonization on the gastric mucosa, directly or indirectly reducing gastric mucosal inflammation, alleviating oxidative stress, and improving gut microbiota. This review will summarize the current research progress on the mechanisms by which fucoidan exerts its anti-Helicobacter pylori effects and explore its potential application in Hp eradication therapy.
文章引用:徐颜, 郝静雯, 田字彬, 于亚男. 岩藻多糖抗幽门螺杆菌作用的研究进展[J]. 临床医学进展, 2024, 14(12): 1150-1156. https://doi.org/10.12677/acm.2024.14123198

参考文献

[1] Marshall, B. and Warren, J.R. (1984) Unidentified Curved Bacilli in the Stomach of Patients with Gastritis and Peptic Ulceration. The Lancet, 323, 1311-1315. [Google Scholar] [CrossRef] [PubMed]
[2] 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
[3] Sugano, K., Tack, J., Kuipers, E.J., Graham, D.Y., El-Omar, E.M., Miura, S., et al. (2015) Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut, 64, 1353-1367. [Google Scholar] [CrossRef] [PubMed]
[4] Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J.P., Liou, J., Schulz, C., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 胃肠病学, 2022, 27(3): 150-162.
[6] Johnson, K.S. and Ottemann, K.M. (2018) Colonization, Localization, and Inflammation: The Roles of H. pylori Chemotaxis in Vivo. Current Opinion in Microbiology, 41, 51-57. [Google Scholar] [CrossRef] [PubMed]
[7] Hernández-Hernández, L.d.C., Lazcano-Ponce, E.C., López-Vidal, Y. and Aguilar-Gutiérrez, G.R. (2009) Relevance of Helicobacter pylori Virulence Factors for Vaccine Development. Salud Pública de México, 51, s447-s454. [Google Scholar] [CrossRef] [PubMed]
[8] 黄凯黎, 黄干荣, 管爱星, 等. 幽门螺杆菌黏附定植在感染发病中的作用机制研究[J]. 中国病原生物学杂志, 2023, 18(10): 1223-1225+1230.
[9] Borén, T., Falk, P., Roth, K.A., Larson, G. and Normark, S. (1993) Attachment of Helicobacter pylori to Human Gastric Epithelium Mediated by Blood Group Antigens. Science, 262, 1892-1895. [Google Scholar] [CrossRef] [PubMed]
[10] Mahdavi, J., Sondén, B., Hurtig, M., Olfat, F.O., Forsberg, L., Roche, N., et al. (2002) Helicobacter pylori Saba Adhesin in Persistent Infection and Chronic Inflammation. Science, 297, 573-578. [Google Scholar] [CrossRef] [PubMed]
[11] Senkovich, O.A., Yin, J., Ekshyyan, V., Conant, C., Traylor, J., Adegboyega, P., et al. (2011) Helicobacter pylori Alpa and Alpb Bind Host Laminin and Influence Gastric Inflammation in Gerbils. Infection and Immunity, 79, 3106-3116. [Google Scholar] [CrossRef] [PubMed]
[12] 李慧敏, 高锦明. NF-κB在幽门螺杆菌诱导胃癌发展及治疗中的作用研究进展[J]. 现代肿瘤医学, 2023, 31(23): 4476-4480.
[13] Olbermann, P., Josenhans, C., Moodley, Y., Uhr, M., Stamer, C., Vauterin, M., et al. (2010) A Global Overview of the Genetic and Functional Diversity in the Helicobacter pylori Cag Pathogenicity Island. PLOS Genetics, 6, e1001069. [Google Scholar] [CrossRef] [PubMed]
[14] Sharndama, H.C. and Mba, I.E. (2022) Helicobacter pylori: An Up-to-Date Overview on the Virulence and Pathogenesis Mechanisms. Brazilian Journal of Microbiology, 53, 33-50. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, H., Zhao, M., Shi, F., Zheng, S., Xiong, L. and Zheng, L. (2023) A Review of Signal Pathway Induced by Virulent Protein CagA of Helicobacter pylori. Frontiers in Cellular and Infection Microbiology, 13, Article 1062803. [Google Scholar] [CrossRef] [PubMed]
[16] Maubach, G., Vieth, M., Boccellato, F. and Naumann, M. (2022) Helicobacter pylori-Induced NF-κB: Trailblazer for Gastric Pathophysiology. Trends in Molecular Medicine, 28, 210-222. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, M., Huang, X., Gao, M., Yang, Z., Fang, Z., Wei, J., et al. (2022) Helicobacter pylori Promotes Inflammatory Factor Secretion and Lung Injury through Vaca Exotoxin-Mediated Activation of NF-κB Signaling. Bioengineered, 13, 12760-12771. [Google Scholar] [CrossRef] [PubMed]
[18] Altobelli, A., Bauer, M., Velez, K., Cover, T.L. and Müller, A. (2019) Helicobacter pylori Vaca Targets Myeloid Cells in the Gastric Lamina Propria to Promote Peripherally Induced Regulatory T-Cell Differentiation and Persistent Infection. mBio, 10, Article 13. [Google Scholar] [CrossRef] [PubMed]
[19] Cook, K.W., Letley, D.P., Ingram, R.J.M., Staples, E., Skjoldmose, H., Atherton, J.C., et al. (2014) CCL20/CCR6-Mediated Migration of Regulatory T Cells to the Helicobacter pylori-Infected Human Gastric Mucosa. Gut, 63, 1550-1559. [Google Scholar] [CrossRef] [PubMed]
[20] Correa, P. (1992) Human Gastric Carcinogenesis: A Multistep and Multifactorial Process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research, 52, 6735-6740.
[21] Fallone, C.A., Moss, S.F. and Malfertheiner, P. (2019) Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology, 157, 44-53. [Google Scholar] [CrossRef] [PubMed]
[22] 吴童, 管爱星, 苏朱娜, 等 幽门螺杆菌耐药流行病学研究现状[J]. 右江民族医学院学报, 2023, 45(5): 816-281.
[23] Nyssen, O.P., Bordin, D., Tepes, B., Pérez-Aisa, Á., Vaira, D., Caldas, M., et al. (2020) European Registry on Helicobacter pylori Management (Hp-EuReg): Patterns and Trends in First-Line Empirical Eradication Prescription and Outcomes of 5 Years and 21533 Patients. Gut, 70, 40-54. [Google Scholar] [CrossRef] [PubMed]
[24] Bujanda, L., Nyssen, O.P., Vaira, D., Saracino, I.M., Fiorini, G., Lerang, F., et al. (2021) Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics, 10, Article 1058. [Google Scholar] [CrossRef] [PubMed]
[25] Kuo, Y., Liou, J., El-Omar, E.M., Wu, J., Leow, A.H.R., Goh, K.L., et al. (2017) Primary Antibiotic Resistance in Helicobacter pylori in the Asia-Pacific Region: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 2, 707-715. [Google Scholar] [CrossRef] [PubMed]
[26] 王鸿, 张甲生, 严银春, 等. 褐藻岩藻多糖生物活性研究进展[J]. 右江民族医学院学报, 2018, 46(2): 209-215.
[27] 闫晨, 邸志权, 朱振娜, 等. 岩藻聚糖硫酸酯FV对大鼠的抗凝血作用及机制研究[J]. 现代药物与临床, 2019, 34(9): 2587-2592.
[28] 张雪琳, 蒋晨, 徐珊, 等. 岩藻多糖对幽门螺杆菌感染后小鼠肠道菌群紊乱的调节作用[J]. 精准医学杂志, 2021, 36(3): 222-226+230.
[29] 巨虎, 刘川川, 王虎, 等. 岩藻多糖调节JAK2/STAT3信号通路保护神经元免受缺氧缺糖/再灌注损伤[J]. 中国高原医学与生物学杂志, 2022, 43(1): 7-17.
[30] Shibata, H., Kimura-Takagi, I., Nagaoka, M., Hashimoto, S., Sawada, H., Ueyama, S., et al. (1999) Inhibitory Effect of Cladosiphon Fucoidan on the Adhesion of Helicobacter pylori to Human Gastric Cells. Journal of Nutritional Science and Vitaminology, 45, 325-336. [Google Scholar] [CrossRef] [PubMed]
[31] Shibata, H., Iimuro, M., Uchiya, N., Kawamori, T., Nagaoka, M., Ueyama, S., et al. (2003) Preventive Effects of Cladosiphon Fucoidan against Helicobacter pylori Infection in Mongolian Gerbils. Helicobacter, 8, 59-65. [Google Scholar] [CrossRef] [PubMed]
[32] Cai, J., Kim, T., Jang, J.Y., Kim, J., Shin, K., Lee, S., et al. (2014) In Vitro and in Vivo Anti-Helicobacter pylori Activities of FEMY-R7 Composed of Fucoidan and Evening Primrose Extract. Laboratory Animal Research, 30, 28-34. [Google Scholar] [CrossRef] [PubMed]
[33] Chua, E., Verbrugghe, P., Perkins, T.T. and Tay, C. (2015) Fucoidans Disrupt Adherence of Helicobacter pylori to AGS Cells in Vitro. Evidence-Based Complementary and Alternative Medicine, 2015, 1-6. [Google Scholar] [CrossRef] [PubMed]
[34] Lutay, N., Nilsson, I., Wadström, T. and Ljungh, Å. (2010) Effect of Heparin, Fucoidan and Other Polysaccharides on Adhesion of Enterohepatic Helicobacter Species to Murine Macrophages. Applied Biochemistry and Biotechnology, 164, 1-9. [Google Scholar] [CrossRef] [PubMed]
[35] 孙静, 邹圆静, 孙璇, 等. 葡萄籽提取物和岩藻多糖组合物抗幽门螺杆菌作用及机制研究[J]. 食品与发酵工业, 2024, 50(18): 279-283.
[36] Vona, R., Pallotta, L., Cappelletti, M., Severi, C. and Matarrese, P. (2021) The Impact of Oxidative Stress in Human Pathology: Focus on Gastrointestinal Disorders. Antioxidants, 10, Article 201. [Google Scholar] [CrossRef] [PubMed]
[37] Gobert, A.P. and Wilson, K.T. (2017) Human and Helicobacter pylori Interactions Determine the Outcome of Gastric Diseases. In: Current Topics in Microbiology and Immunology, Springer, 27-52. [Google Scholar] [CrossRef] [PubMed]
[38] Handa, O., Naito, Y. and Yoshikawa, T. (2010) Helicobacter pylori: A Ros-Inducing Bacterial Species in the Stomach. Inflammation Research, 59, 997-1003. [Google Scholar] [CrossRef] [PubMed]
[39] Chen, B., Li, W., Li, T., Chan, Y. and Wu, C. (2022) Fucoidan from Sargassum Hemiphyllum Inhibits Infection and Inflammation of Helicobacter pylori. Scientific Reports, 12, Article No. 429. [Google Scholar] [CrossRef] [PubMed]
[40] Ni, L., Wang, L., Fu, X., Duan, D., Jeon, Y., Xu, J., et al. (2020) In Vitro and in Vivo Anti-Inflammatory Activities of a Fucose-Rich Fucoidan Isolated from Saccharina Japonica. International Journal of Biological Macromolecules, 156, 717-729. [Google Scholar] [CrossRef] [PubMed]
[41] Kim, T., Choi, E., Kim, J., Shin, K., Lee, S., Choi, Y., et al. (2014) Anti-Helicobacter pylori Activities of FEMY-R7 Composed of Fucoidan and Evening Primrose Extract in Mice and Humans. Laboratory Animal Research, 30, 131-135. [Google Scholar] [CrossRef] [PubMed]
[42] Apostolova, E., Lukova, P., Baldzhieva, A., Katsarov, P., Nikolova, M., Iliev, I., et al. (2020) Immunomodulatory and Anti-Inflammatory Effects of Fucoidan: A Review. Polymers, 12, Article 2338. [Google Scholar] [CrossRef] [PubMed]
[43] Wang, S., Tian, Z.B., Chen, J.W., et al. (2023) Effect of Fucoidan on Gut Microbiota and Its Clinical Efficacy in Helicobacter pylori Eradication: A Randomized Controlled Trial. Journal of Digestive Diseases, 24, 461-471.